The Role of Senolytics in Optimizing Therapy-Induced Senescence for Cancer Treatment

Senescent fibroblasts within the tumor microenvironment (TME) can produce Fas ligand (FasL) and trigger apoptosis of infiltrating T and NK cells, thereby undermining anti-tumor immunity and aiding immune escape [103].

Given the risk of senescence escape and the detrimental effects of lingering SASP (Senescence-Associated Secretory Phenotype), therapeutic approaches aimed at selectively eliminating senescent cells—senolytics—offer a rational complement to senescence-inducing therapies. Senolytics represent an emerging class of therapeutics that could significantly enhance the efficacy and safety of therapy-induced senescence (TIS) (Table 1) [104]. While TIS serves as a potent anti-tumor mechanism by enforcing irreversible growth arrest and promoting immune activation through the SASP, the accumulation of senescent cells and chronic SASP can paradoxically promote inflammation, tumor progression, and immunosuppression if senescent cells are not efficiently cleared. This creates a therapeutic window for senolytics, which can be employed after the immune-priming phase of TIS to remove residual senescent cells, thereby mitigating the long-term pro-tumorigenic risks associated with chronic SASP [105–107]. For instance, a study showed that cancer therapies like doxorubicin and etoposide can induce tumor cell senescence, which may contribute to disease relapse. However, these TIS cells were found to be selectively sensitive to the senolytic agent ABT-263 (navitoclax). By disrupting BCLXL–BAX interactions, ABT-263 promotes apoptosis in senescent cells, effectively eliminating them. In vivo, sequential treatment with chemotherapy followed by ABT-263 led to sustained tumor suppression. These findings suggest that combining senescence-inducing therapies with senolytic agents may enhance treatment efficacy and reduce the risk of cancer recurrence [105].

Moreover, the timing and sequencing of senolytics are critical for maximizing synergy with immune therapies. Administering senolytics too early may prematurely deplete senescent cells before they can fully exert their immunostimulatory effects, such as SASP-mediated recruitment of immune effector cells. Conversely, delayed administration, after peak immune infiltration, allows for sufficient immune priming while minimizing chronic SASP-associated toxicity [108, 109]. This strategy is supported by preclinical models in which CDK4/6 inhibitors were used to induce senescence, followed by immune therapy and then senolytic treatment, resulting in improved tumor regression and reduced systemic inflammation [65]. Finally, senolytics may also target senescent stromal and endothelial cells within the TME, which can support tumor survival and contribute to therapy resistance. Their clearance not only limits pro-tumorigenic signaling but may also enhance immune cell infiltration and drug delivery by normalizing the extracellular matrix and vasculature [110–112].

Several rigorous preclinical studies demonstrate that conventional cytotoxics and targeted agents that induce senescence can sensitize tumors to immune checkpoint blockade [113]. In mouse models of breast and brain-metastatic breast cancer, induction of senescence with doxorubicin or combinations that trigger durable cell-cycle exit increased CD8+ T-cell infiltration and antigen-presentation signatures. When combined with anti-PD-1/PD-L1 antibodies, these regimens produced greater tumor regression and prolongation of survival than either therapy alone. Depletion of CD8+ T cells abrogated the benefit, implicating adaptive immunity as the effector of synergy. These studies also report that SASP drives dendritic cell maturation and chemokine gradients that recruit effector T cells, providing a mechanistic link between TIS and increased ICI responsiveness [114].

Mechanistic molecular work has refined why senescent cells can both help and hinder immunotherapy. Recent reports demonstrate that senescent tumor cells often upregulate immunoregulatory molecules—most notably PD-L1—through transcriptional and post-translational mechanisms. One high-profile study identified ribophorin-1–dependent glycosylation as a regulator of PD-L1 stabilization in senescent cancer cells, which can paradoxically shield them from T-cell killing unless PD-1/PD-L1 is blocked. Thus, TIS can create a tumor state that is simultaneously more immunogenic (enhanced antigen presentation, SASP-driven recruitment) and more dependent on immune checkpoints for immune escape—explaining why combining TIS inducers with checkpoint blockade often yields additive or synergistic results in preclinical systems [115, 116]. CDK4/6 inhibitors are among the best-characterized clinically relevant senescence inducers with immunomodulatory effects. Multiple preclinical investigations reported that palbociclib/abemaciclib treatment increases Type I/II interferon signaling, MHC-I expression, and intratumoral T-cell activation. In murine tumor models, these changes sensitize tumors to PD-1 blockade, producing improved tumor control versus monotherapy. Early-phase clinical work has explored this combination: a phase I/II trial combining palbociclib with pembrolizumab (and endocrine therapy where applicable) demonstrated that the regimen is feasible and signals of clinical activity exist in selected breast cancer cohorts, although definitive efficacy and optimal sequencing remain under study. Importantly, these clinical datasets emphasize dosing/sequence tradeoffs because CDK4/6 inhibitors also transiently suppress T-cell proliferation—an effect that can blunt combination benefit if timing is suboptimal [113, 117]. For further insights into molecular cancer research, please refer to Molecular Cancer .